A comparative clinical trial to study the effects of surgery combined with radiation therapy and surgery combined with 5- Fluorouracil in patients with ear Keloids
Comparison of efficacy of excision with intralesional 5- fluorouracil and excision with radiotherapy in the treatment of ear keloids: randomised control trial
Farrukh Aslam Khalid
120 participants
May 17, 2014
Interventional
Conditions
Summary
After approval from Ethical committee of our hospital, 120 patients presenting in the Department of Plastic Surgery through out patient department of Jinnah hospital, fulfilling the selection criteria will be included in the study. An informed consent will be obtained from them. Patients will be divided randomly in two groups by the help of random number table; Group A will be the patients of post excision radiotherapy and group B will be the patients post excision 5-FU. All the patients will be photographed and baseline assessment will be done before initiation of treatment by filling the proforma attached. All patients will undergo excision of the keloid under local anesthesia [2% lignocaine with 1:100,000 Adrenaline]. In group A, all patients will receive radiotherapy of total 10 Gy (2 fractions in two days) starting within 24 hours of excision. The target volume will be limited to the scar plus a 0.5-cm margin on both sides of suture lines. Ear lobe will be tapered away from the face and a direct anteroposterior field (with a small cone) will be used. In group B, excision followed by Intralesional 5-Fluorouracil [5-FU] injection in the dose of 50-150 mg divided between the excision margin and the wound bed. 5-FU will be given at two weekly interval. After giving local anesthesia [2% lignocaine +1:100,000 Adrenaline] using a 3cc syringe, 5-FU will be injected in the body of scar by using a 1cc syringe with premounted 27G needle, until slight blanching will be clinically visible. Assessment of patient will be done at 4, 8 weeks of treatment and 4 weeks after completion of treatment and then 6 monthly till 1 year for recurrance and mean scar reduction by the researcher.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In group B (interventional group) patients will undergo excision of the keloid under local anesthesia [2% lignocaine + 1:100,000 Adrenaline] using 3cc syringe followed by Intralesional 5-Fluorouracil [5-FU] injection with 1cc syringe and 27G needle average volumes to be 0.2 to 0.4 ml/cm2 in divided doses between the excision margin and the wound bed. With maximum dose not exceeding 150mg (50mg/ml injection). All patients will be seen at 7th day postoperatively for suture removal and then again at approximately 1 month and 2 months postoperatively for 5-FU injection. The dose of subsequent injection will be same. If there is no evidence of recurrence at the 2-month postoperative visit, the injections will be stopped. For those that showed hypertrophy either at completion of the second injection or on subsequent return, the injections will be continued at regular intervals in an attempt to arrest the inflammatory process. The injections will be stopped when the hypertrophy will worsen to the point of keloid formation or the hypertrophic process will subside with eventual flattening and resolution of the scar.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12614000368639